Read More About Medicines in Development for Chronic Obstructive Pulmonary Disease (COPD)

America’s biopharmaceutical research companies are working on 54 medicines to treat chronic obstructive pulmonary disease (COPD), according to a report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA). These exciting therapies are in late-stage development, meaning they are either in clinical trials or awaiting review by the Food and Drug Administration (FDA).

Read More About Medicines in Development for Biologics

America’s biopharmaceutical research companies are using biological processes to develop 907 medicines and vaccines targeting more than 100 diseases, according to a new report from PhRMA. The medicines and vaccines – all in human clinical trials or under review the U.S. Food and Drug Administration (FDA) – include 338 monoclonal antibodies, 250 vaccines, 93 recombinant proteins, 60 cell therapies, 46 gene therapies and 30 antisense medicines.  

Medicines in Development for Older Americans

America’s biopharmaceutical research companies currently are developing 435 innovative new medicines to target 15 leading chronic conditions affecting the Medicare population.  These medicines in development – all either in clinical trials or under review by the Food and Drug Administration (FDA) – include 110 for diabetes, 62 for rheumatoid arthritis and osteoarthritis, 67 for Alzheimer’s disease, 61 for heart disease and 40 for chronic obstructive pulmonary disease (COPD), according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA).

Backgrounder: Selected Biologics in Development

Alzheimer’s disease affects more than 5 million Americans, according to the Alzheimer’s Association.  It also costs the U.S. health care system $200 billion a year. These sobering statistics are projected to get much worse as the 76 million American baby boomers age.A gene therapy for the treatment of Alzheimer's disease in clinical trials is designed to deliver nerve growth factor (NGF) to the brain.  NGF is a naturally occurring protein important for neuron survival.

Medicines in Development: Biologics 2013

Medicines in Development: Asthma

Read More About Medicines in Development for Asthma

America’s biopharmaceutical research companies are working on 74 medicines to treat asthma, according to a report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA). All of the medicines are either in clinical trials or awaiting review by the Food and Drug Administration (FDA).

Medicines in Development for Arthritis

America’s biopharmaceutical research companies are currently developing 198 medicines to help the more than 50 million Americans afflicted with at least one of the 100 different musculoskeletal disorders, including arthritis. All of the medicines are either in clinical trials or awaiting review by the U.S. Food and Drug Administration.

Read More About Medicines in Development for Alzheimer's Disease

America’s biopharmaceutical research companies are investigating or developing 93 medicines to help the more than five million patients in the United States who are living with Alzheimer’s. The medicines in development – all in either clinical trials or under review by the Food and Drug Administration – include 81 for Alzheimer’s, 11 for cognition disorders and 2 for dementias, according to a new report released by the Pharmaceutical Research and Manufacturers of America (PhRMA).

Profiles and Reports

Continued scientific and technological innovations are critical to fostering sustained economic growth, global competitiveness, and most importantly, helping patients live longer, healthier, and more productive lives. The U.S. innovative biopharmaceutical industry is committed to building on new scientific discoveries and technological advances, relying on a workforce with education and skills in science, technology, engineering, and math (STEM).

Pages

Subscribe to RSS - Innovation